IND of Sirotinib, anti-oncology new drug, is approved by CFDA
2015-07-17 14:36:34 Author:admin
      IND filing of Sirotinib (XZP-5491), submitted at the end of June 2015, has been approved by CFDA (The filing numbers are CXHL1501499 and CXHL1501499). 
      The second anti-cancer new drug developed by XuanZhu, Sirotinib is a new generation, irreversible pan-Her inhibitor for the treatment of advanced cancers, including esophageal, gastric and lung carcinoma. Our comprehensive preclinical studies demonstrate that Sirotinib is potentially effective in a broad range of cancers, especially esophageal squamous cell carcinoma (ESCC), which is most common in China. We are confident that Sirotinib will be a success on the way to the market, bringing greatest benefit to Chinese patients and maximal value to Sihuan and XuanZhu.

Email | Terms of Use | Contact us

2014版权?轩竹生物科技有限公司保留所有权利 鲁ICP备09030169号